The gut microbiota associated with high-Gleason prostate cancer.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Aug 2021
Historique:
revised: 11 05 2021
received: 11 03 2021
accepted: 19 05 2021
pubmed: 30 5 2021
medline: 20 8 2021
entrez: 29 5 2021
Statut: ppublish

Résumé

We have found that intestinal bacteria and their metabolites, short-chain fatty acids (SCFAs), promote cancer growth in prostate cancer (PCa) mouse models. To clarify the association between gut microbiota and PCa in humans, we analyzed the gut microbiota profiles of men with suspected PCa. One hundred and fifty-two Japanese men undergoing prostate biopsies (96 with cancer and 56 without cancer) were included in the study and randomly divided into two cohorts: a discovery cohort (114 samples) and a test cohort (38 samples). The gut microbiota was compared between two groups, a high-risk group (men with Grade group 2 or higher PCa) and a negative + low-risk group (men with negative biopsy or Grade group 1 PCa), using 16S rRNA gene sequencing. The relative abundances of Rikenellaceae, Alistipes, and Lachnospira, all SCFA-producing bacteria, were significantly increased in high-risk group. In receiver operating characteristic curve analysis, the index calculated from the abundance of 18 bacterial genera which were selected by least absolute shrinkage and selection operator regression detected high-risk PCa in the discovery cohort with higher accuracy than the prostate specific antigen test (area under the curve [AUC] = 0.85 vs 0.74). Validation of the index in the test cohort showed similar results (AUC = 0.81 vs 0.67). The specific bacterial taxa were associated with high-risk PCa. The gut microbiota profile could be a novel useful marker for the detection of high-risk PCa and could contribute to the carcinogenesis of PCa.

Identifiants

pubmed: 34051009
doi: 10.1111/cas.14998
pmc: PMC8353908
doi:

Substances chimiques

DNA, Bacterial 0
DNA, Ribosomal 0
RNA, Ribosomal, 16S 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3125-3135

Subventions

Organisme : Yakult Bio-Science Foundation
Organisme : Japanese Urological Association

Informations de copyright

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Nat Commun. 2015 Mar 11;6:6528
pubmed: 25758642
Annu Rev Immunol. 2017 Apr 26;35:199-228
pubmed: 28142322
Cell Host Microbe. 2016 Apr 13;19(4):455-69
pubmed: 27078067
Urology. 2018 Jan;111:122-128
pubmed: 28888753
Oncotarget. 2018 Apr 3;9(25):17915-17927
pubmed: 29707157
Cancer Discov. 2017 May;7(5):522-538
pubmed: 28202625
Eur Urol. 2018 Nov;74(5):575-582
pubmed: 30007819
Cancers (Basel). 2019 Aug 12;11(8):
pubmed: 31408948
Prostate Cancer Prostatic Dis. 2018 Nov;21(4):539-548
pubmed: 29988102
Science. 2006 Jun 2;312(5778):1355-9
pubmed: 16741115
Cell Host Microbe. 2013 Aug 14;14(2):195-206
pubmed: 23954158
Inflamm Bowel Dis. 2017 Jan;23(1):116-125
pubmed: 27893543
Prostate. 2019 Jan;79(1):81-87
pubmed: 30117171
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):345-354
pubmed: 29795140
Nature. 2006 Dec 21;444(7122):1027-31
pubmed: 17183312
PLoS One. 2011;6(9):e24143
pubmed: 21915291
Microbiome. 2018 Apr 11;6(1):70
pubmed: 29642940
Oncotarget. 2017 Jan 3;8(1):444-457
pubmed: 27880935
Cancer Sci. 2021 Aug;112(8):3125-3135
pubmed: 34051009
Front Cell Infect Microbiol. 2016 Dec 09;6:179
pubmed: 28018861
Am J Clin Nutr. 2019 Sep 1;110(3):701-712
pubmed: 31291462
Science. 2012 Jun 8;336(6086):1255-62
pubmed: 22674335
Oncol Lett. 2019 Jun;17(6):5050-5056
pubmed: 31186716
Int J Med Sci. 2017 Jan 1;14(1):1-12
pubmed: 28138303
Int J Mol Sci. 2020 Feb 20;21(4):
pubmed: 32093338
Cancer Res. 2021 Aug 1;81(15):4014-4026
pubmed: 34039634
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14691-6
pubmed: 20679230
Sci Rep. 2016 Jul 21;6:30028
pubmed: 27443609
J Clin Med. 2020 Aug 18;9(8):
pubmed: 32824865
FEMS Microbiol Ecol. 2017 Dec 1;93(12):
pubmed: 29126267
Gynecol Oncol. 2019 Nov;155(2):237-244
pubmed: 31500892
J Urol. 2018 Jan;199(1):161-171
pubmed: 28797714
Genome Biol Evol. 2014 Mar;6(3):703-13
pubmed: 24625961
Front Immunol. 2020 Jun 09;11:906
pubmed: 32582143
J Nutr. 2009 Sep;139(9):1685-91
pubmed: 19640972
Sci Rep. 2019 Jul 29;9(1):10923
pubmed: 31358825
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
Carcinogenesis. 2019 Jul 6;40(6):749-764
pubmed: 30794288
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Nat Med. 2019 Jun;25(6):968-976
pubmed: 31171880
Sci Rep. 2016 Mar 15;6:23075
pubmed: 26975620
Sci Rep. 2019 Sep 25;9(1):13831
pubmed: 31554861
Clin Cancer Res. 2018 Sep 1;24(17):4309-4318
pubmed: 29776955
DNA Res. 2016 Apr;23(2):125-33
pubmed: 26951067
BMC Genomics. 2019 Feb 18;20(1):146
pubmed: 30777011
Immunity. 2014 Jan 16;40(1):128-39
pubmed: 24412617
J Acad Nutr Diet. 2018 Apr;118(4):714-723.e1
pubmed: 27988219

Auteurs

Makoto Matsushita (M)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.

Kazutoshi Fujita (K)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Japan.

Daisuke Motooka (D)

Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Koji Hatano (K)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.

Shota Fukae (S)

Department of Urology, Osaka Police Hospital, Osaka, Japan.

Norihiko Kawamura (N)

Department of Urology, Osaka General Medical Center, Osaka, Japan.

Eisuke Tomiyama (E)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.

Yujiro Hayashi (Y)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.

Eri Banno (E)

Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Japan.

Tetsuya Takao (T)

Department of Urology, Osaka General Medical Center, Osaka, Japan.

Shingo Takada (S)

Department of Urology, Osaka Police Hospital, Osaka, Japan.

Shinichi Yachida (S)

Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Suita, Japan.

Hirotsugu Uemura (H)

Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Japan.

Shota Nakamura (S)

Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Norio Nonomura (N)

Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH